Focuses on developing small molecule therapies for devastating diseases with high unmet medical needs.
Entrada Therapeutics, Inc. is a pioneering biotechnology company focused on advancing therapies for a spectrum of neuromuscular diseases. Leveraging its innovative endosomal escape vehicle (EEV) platform, Entrada Therapeutics develops a diverse portfolio of therapeutic programs based on oligonucleotides, antibodies, and enzymes.
At the forefront of its pipeline, Entrada Therapeutics is advancing ENTR-601-44, its lead product candidate currently in preclinical trials for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. The company also develops EEV-PMO-CAG specifically targeting myotonic dystrophy type 1, underscoring its commitment to addressing unmet medical needs in neuromuscular disorders.
Formerly known as CycloPorters, Inc., Entrada Therapeutics rebranded in October 2017 to reflect its expanded focus and innovative approach to therapeutic development. Since its inception in 2016, the company has been headquartered in Boston, Masachusetts, strategically positioning itself within a vibrant biotechnology hub.
With a dedicated team and a robust pipeline, Entrada Therapeutics is poised to make significant strides in the treatment landscape of neuromuscular diseases. Through its pioneering EEV platform, the company aims to deliver transformative therapies that enhance the lives of patients worldwide.